Think It’s Too Late to Buy This Leading Biotech Stock? Here’s Why There’s Still Time.

0 2 minutes read

Think Its Too Late to Buy This Leading Biotech Stock.jpeg

Viking Therapeutics stocks achieved great success due to disappointing endurance data in the second stage experience.
The company still has strategic options, and may attract the attention of large pharmaceutical companies that have greater experience in clinical trials.
10 shares of Nodi is better than Viking Therapeutics ›

The market was lower than admiration for the higher results from Vicing treatments‘ (Nasdaq: vktx) The second stage of oral drafting experience for its anti -obesity drug VK2735. Disappointment has created a feeling that the arrow lacks any incentive in the short-term-results 3 results from VK2735 in the subcutaneous (injection) form until 2027-and that excitement about inventory focused mainly on the formulation of the mouth.

However, this reaction may be very hasty, and there is still time to buy in health care stocks.

Photo source: Getty Images.

The experience of oral doses in stage 2 showed great effectiveness. However, investors have been disappointed due to safety and endurance data, especially the stop rate of 20 % due to negative events. This is a sensitive issue here, especially as Vizar Oral weight loss development stopped in the same category that also had disappointingly calculated data in the experiment.

The stop rates due to the harmful effects in the adventure experience were higher than those in the treatment groups in the experiments of stage 3 of weight loss medications by orally by Eli Lily and Novo Nordsk.

a company	medicine	trial	The stop rate due to the harmful effects (treated)	The stop rate due to the harmful effects (fake)	Reducing body weight
Vicing treatments	VK2735 (oral)	Project (Stage 2)	20 %	13 %	12.2 %*
Novo Nordsk	Semaglutide (oral)	Oasis-1 (stage 3)	6 %	4 %	15 %
Eli Lily	Orforipron	Achieve 1 (stage 3)	10.3 %*	2.6 %	12.4 %*

Data sources: VIKING THEREREUTICS, ELI Lilly, Medical and Vascular Academy Academy. *At the top dose

However, a larger pharmaceutical company may be interested in gaining Vikings or partnership with it to develop VK2735 in an oral form and help it by testing stage 3, or instead, take it to stage 3 after improving the dose. Or it can be used as a maintenance treatment for patients who have already lost weight through treatment.

Viking may have more options than the market believes.

Before buying shares in Vikings treatments, think about this:

the Motley Adviser is a lie The analyst’s team has just identified what they think 10 best stocks For investors to buy now … Viking Therapeutics was not one of them. The ten shares that made the pieces can produce monster revenues in the coming years.